TITLE PAGE

Adjunct Therapeutic Role of Potassium in Rheumatoid Arthritis: A Randomized Controlled Trial with Suitable Diet and Novel Food Supplement in Symptomatic Patients on Standard Rheumatology Care.

*Kianifard Toktam, **Saluja Manjit, *** Sarmukaddam Sanjeev, # Venugopalan Anuradha, ## Chopra Arvind

*MSc, PhD, Dietitian and Nutritionist, Center for Rheumatic Diseases, Pune, India

**MSc, Co-ordinator Research and Trials, Center for Rheumatic Diseases, Pune, India

***MSc, PhD, Senior Biostatistician, Center for Rheumatic Diseases, Pune, India

MSc, PhD, In-charge CRD R & D Laboratory, Center for Rheumatic Diseases, Pune, India

MD, FRCP, Director and Chief Rheumatologist, Center for Rheumatic Diseases, Pune, India (ORCID ID: 0000-0002-4347-9651)

KEY WORDS: Potassium , Diet, Rheumatoid arthritis, Pain, Vegetarian Diet

Word Count: 3865

Address for Correspondence:

Dr Arvind Chopra, MD

Centre for Rheumatic Diseases,

Hermes Elegance, 1988 Convent Street, Camp,

Pune 411001 INDIA

Tele: +91 9822039297;

Email: arvindchopra60@hotmail.com

ABSTRACT

Introduction: Earlier food surveys showed deficient dietary potassium in rheumatoid arthritis (RA) .

Objective: To evaluate an adjunct role of oral potassium to reduce joint pain in RA

Methods: 172 consenting and eligible symptomatic patients (median duration 6.5 years) on standard care were randomized into an assessor blind, parallel efficacy, controlled, multi-arm single center study (80% power) of 16 weeks duration- Arm A (potassium rich vegetarian diet), Arm B (Arm A plus novel potassium food supplement) and Arm C (Control, regular diet). Standard efficacy (American College of Rheumatology) and safety, and diet intake (three-day recall) were assessed at monthly intervals (protocol). Standard statistical tests were used; significant $p < 0.05$, two sided). Study arms were well matched at baseline and RA medication remained fairly stable. Patients in Arm A and B met the pre-set target for increased potassium intake (diet analysis, India standards) and remained normokalemic. Diet remained unchanged in Arm C.

Results: 155 patients (90.1%) completed and several showed improvement (best in Arm B). Potassium intervention was safe and well tolerated. Adverse events were mild; none caused patient withdrawal. On comparison, the mean change in pain visual analogue scale (-2.23, 95% confidence interval -2.99 to -1.48) at week 16 (primary efficacy) from baseline in Arm B was significantly superior as per protocol analysis. A high daily potassium intake (5-7.5 gm, Arm B) was significantly associated with low pain (study

completion); Odds Ratio 2.5, Univariate Analysis and Likelihood Ratio 2.9, Logistic Regression. Compliance (intervention), diet record and analysis, RA medication and absence of placebo were potential confounders.

Conclusion: High oral potassium intake based on a suitable diet and food supplement, reduced joint pain and improved RA. It was a safe adjunct and ought to be considered for standard care in RA. Further validation studies are required.

Trial Registration: Clinical Trial Registry of India- CTRI/2022/03/040726

Abstract Word Count: 298

KEY MESSAGE

What is already known on the topic?

1)Potassium is a vital micronutrient in health, but little is known about its role in RA.

2)Patients suffering from symptomatic RA may consumed potassium deficient diet

What this study adds?

1)Increased potassium intake based on a suitable vegetarian diet and a novel food supplement may joint pain and improve RA

2)High oral potassium intake was found safe and well tolerated

How this study might affect research, practise or policy/

1)A high potassium intake based on vegetarian diet and food is a useful adjunct to manage difficult symptomatic RA in clinical practise.

2) The current recommendations/guidelines on potassium intake should be revised

INTRODUCTION

Rheumatoid arthritis (RA) is a difficult to treat life-long autoimmune disease with several systemic complications, poor quality of life and reduced longevity[1]. The burden of disease is enormous and rheumatology care in India is inadequate [2]. Standard guidelines focus on drugs and often neglect adjuvant therapies such as diet [3]. Since ancient times, diet has been pivotal in the management of arthritis [4]. The role of diet is allegedly multifaceted but scientific evidence is limited [5, 6].

A recent food survey in RA reported low potassium intake [7]. Potassium is an essential micronutrient, but little is known about the role in RA [8, 9]. Weber (1974) advocated a strong etiological link [10]. A relatively low serum potassium in RA was reported in population surveys (NHANES, USA) (11). Low potassium body status was reported using radioisotope labelling[12]. A daily administration of high dose of potassium chloride (mixed in grape juice) for 28 days showed significant improvement in 38 patients of RA in a randomized control study [13].

The primary objective of the current randomized control study was to investigate the adjunct therapeutic role of oral potassium in RA. The primary hypothesis was that potassium reduced joint pain in RA. In view of safety and tolerability concerns, we selected potassium rich vegetarian diet and a novel potassium enriched food supplement as active intervention.

METHODS AND PATIENTS

This was a non-commercial investigator- initiated study and approved by the local (CRD) ethics committee on 04 Feb 2014. The protocol adhered to the tenets of the 'Helsinki Declaration' (updated) and standard GCP/ICH and national guidelines and was registered [14, 15]. The study was completed by Aug 2015.

Study Design

This was a randomized, single blind (assessor), active control, parallel efficacy, drug trial study of 16 weeks duration with 3 treatment arms. It was carried out in a community-based rheumatology center (CRD). A pre-planned potassium rich vegetarian diet was administered in Arm A and Arm B but with an added potassium enriched food supplement in Arm B. Routine diet was used as a control (Arm C). Following enrollment, each participant was examined at monthly interval till week 16. Participants received a modest travel/meal allowance and free of cost investigations and food supplement .

Selection

Interested patients from the CRD clinic volunteered and signed an informed consent. Those found eligible on screening were selected by the rheumatologist (AC) as per the requirements of the protocol [15].

Inclusion criteria included (i) adult patient of RA (ACR 1987) [16] (ii) disease duration of at least 6 months (iii) pre-enrolment supervised standard care of 16 weeks duration (iv) pre-enrolment painful joints of 8 weeks duration (v) maximum pain (joints) record of ≥ 4 cms on a visual analogue scale (VAS) in the previous 24 hours (screening). Exclusion criteria included (i) daily dose of 10 mg or more prednisolone anytime during the previous four weeks (ii) abnormal serum creatinine, blood urea nitrogen assay and serum potassium (≥ 5.5 mEq/L) assay (iii) any medication known to effect body potassium.

Efficacy

The primary efficacy was an improvement in the pain visual analogue scale at week 16 (study completion) from baseline. There were several secondary efficacy measures of disease activity and function.

Procedures

Pre-Randomization Counselling: A comprehensive information document was explained and provided to the participant. They were informed that the adequacy of their routine diet will also be evaluated. Based on study results, a better diet advise may be provided.

Randomization/Enrolment: A standard computer-generated randomization schedule was provided by the biostatistician (SS). Participants were randomized and enrolled by the study coordinator (MS) on a first come first serve basis.

Diet food record: The participants completed the diet record in a face-to-face interview with TK using a validated questionnaire and standard household measures [9]. The diet consumed over 3 previous successive days was retrospectively recorded at all study visits beginning with the randomization.

Clinical**:** The rheumatologist and designated paramedic were blinded (assessor) to the treatment allocation when assessing efficacy and adverse events (AE).

Efficacy measures included a 68/66 joint count for pain/tenderness and swelling [17]. The pain VAS was a 10 cm long horizontal scale; 0 for nil pain and 10 for maximum pain. A Likert scale with 5 categories (asymptomatic to severe) was used to record physician and patient global assessment. A questionnaire-based RA pain score instrument recorded qualitative pain; higher

score meant worst pain (range 0-144) [18]. The functionality/daily activities were assessed by a validated modified Stanford health assessment questionnaire (HAQ); higher score indicated more difficulty (range 0-24) [19]. Short form 36 (SF 36), with permission from the vendor, assessed physical and mental health (quality of life); higher score meant better health [20]. Improvement and disease activity was assessed by standard composite indices [21].

Others: Routine investigations were carried out as per standard care in RA and for safety of potassium administration. Serum cortisol and spot urinary potassium assay were done.

Study Intervention

A potassium rich vegetarian diet (Arms A and B) and a novel potassium enriched food supplement (Arm B) were active interventions. Placebos were not used. Patients followed routine meal timings (thrice a day) and were not to fast or consume any other kind of diet.

Diet/Supplement Target: The potassium rich diet was to provide at least 3500 mg of elemental potassium daily and was guided by the recommended daily allowance (RDA) in India [22, 23]. The addition of food supplement in Arm B was meant to further increase the daily potassium intake to about 5.5 gm; daily supplement intake provided 1.7-2 gm .

Diet Brochure (Arms A and B): A study diet brochure was prepared and provided to the participants, and explained by TK in a face-to-face interview for strict compliance. In brief, the daily meal was prepared by making choices from the list of food items provided under 4 categories (vegetables, fruits, pulses and cereals). The daily quantity required by the participant was described. A proportionate increase in the latter could be used to make a family meal. Guidance was provided on cooking meal, use of salt and spices, and water and milk

consumption. The brochure catered to the local eating habits of the community, and cost and availability of food items. Non-vegetarian food items were discouraged.

Potassium Food Supplement (Arm B): One hundred and forty-two gram (1 unit) of supplement contained green gram (V radiate, 25 gm), cow pea (V unguiculata, 25 gm, coriander seed (C sativum, 25 gm), cumin seed (C cyminum, 25 gm) and 42 gm of oral rehydration salt (Indian pharmacopeia, 3 gm potassium chloride, 5.2 gm sodium chloride, 5.8 gm trisodium citrate, 27 gm glucose). The latter contained 2638 mg elemental potassium (green gram 294.6 mg, cow pea 287 mg, coriander seed 247.4 mg, cumin seed 245 mg, oral rehydration salt 1564 mg); natural ingredients were analysed as per India food composition tables [30].

The dose was 3 heaped tablespoon (provided) to be taken twice a day with a glass of water immediately after a meal. Each participant received a five-week supply of pre-packed supplement every 4 weeks (study visits) and beginning at baseline. The supplement was not to be shared.

An accredited food lab carried out a comprehensive analysis of the novel food supplement which included shelf life and safety (microbial and toxin load) assay, and the results were published in the patent document [24].

Control Diet (Arm C): The patients were advised to continue their routine diet as per their preference and the earlier guidance from their rheumatologist.

Compliance: Participants were to strictly follow the diet and other advise as per protocol. They were reminded every 10-14 days by a telephonic call (nurse/paramedic). The unused portion of the food supplement returned at study visit was carefully weighed and recorded for compliance

and consumption. The participants were made aware that the urinary potassium assay would also show the compliance with the diet advise.

Concurrent medication

Participants continued previous RA medication. The study rheumatologists were encouraged to keep the medication stable but were permitted to modify as per clinical judgement. The pain medication was to be used sparingly on a need basis for severe/intolerable pain. Other co-morbid disorders were treated by the primary care physician.

Statistical Plan and Analysis

There was no prior data available to guide sample size. As the primary objective was to evaluate an adjunct role, a modest effect size for pain relief by potassium intervention (Arm B) was assumed; 10% superior to the control [25]. Based on sample size tables and an expected 20% drop out rate , 171 subjects were required (80% power , significant $p < 0.05$, two tailed). There were 57 participants in each study arm.

The diet data (DFR) was analyzed by TK in a blind manner daily average consumption calculated. Energy and nutrient measures were quantified based on the 'Food Composition Tables' (uncooked and cooked foods) [29,30,31]. In case of Arm B, the average daily consumption of potassium and other nutrients contained in the food supplement was added to the diet-based average. It was decided a-priori to use the diet analysis results at week 16 for efficacy and compliance.

Both intention to treat (ITT) with last observation carried forward and per protocol (completer) analysis was carried out. Standard statistical soft-ware package (IBMSPSS-20, version 2015 and

2018) were used. Standard correction was applied for repeated measures. Both parametric (One way ANOVA) and non-parametric (Mann Whitney statistic, KW signed rank test) tests were used; Chi-square test for categorical data. Unless stated otherwise, all p values in the current report pertain to ANOVA.

Though not intended for the current report, several regression models (including logistic regression) were run to determine predictors of response using clinical, medication and diet and nutrient variables, and limited results are presented (see Supplement File-Tables 6-8).

OBSERVATIONS AND RESULTS

172 patients were randomized and 155 (90.1%) completed the study (per protocol analysis); one withdrew consent following randomization (Fig 1). Seventeen (9.9%) patients withdrew but non due to an AE.

The study arms were matched, and patient suffered from moderately active RA and were on standard care (Tables 1-2). Fifty-one patients (29.6%) recorded co-morbid disorders- 10 diabetes, 27 hypertension , 7 ischemic heart disease , 34 chronic acid-peptic disorders , 7 hemorrhoids , 5 renal calculi and 8 hypothyroidism ; number of patients shown. Five patients showed rheumatoid nodules. None suffered from clinically apparent extra-articular complication.

Diet

The analysis of diet and nutrients is shown in Table 2. A further description of oral potassium intake is shown in Table 3. The daily potassium intake was increased in both the active intervention arms though several fold in Arm B (median 5648 mg, range 4365-7545 mg). 100% patients in Arm B met the preset RDA for potassium; 46% Arm A and 30% Arm C. 84 %

patients in Arm B consumed 5 gm or more of potassium daily. There were no significant differences in the urinary potassium assay by study groups (Supplementary File-Table 1).

The mean intake of potassium at baseline was less than 2750 mg in each of the study arms and substantially lower than the RDA for India (Table 2); 3225 mg women, and 3750 mg men [19]. Following enrolment, the intake of several nutrients was increased in the intervention arms: Arm B more than Arm A (Table 2). The diet energy consumption and nutrient was mostly unchanged in control Arm C.

Less than 7% of patients (especially Arm C) recorded consumption of eggs, red meat and fish.

Safety and Tolerability

Table 4 shows the AE profile. AE were reported by 14 patients in Arm A, 16 patients in Arm B and 11 patients in Arm C (p=0.67, Chi-square statistic). They were mild and mostly related to abdominal complaints, and none were serious. Three patients in Arm B reported episodes of abdominal pain/discomfort of mild-moderate intensity after consuming food supplement. Laboratory investigations (routine hematology, metabolic renal and hepatic) including serum potassium assay were within normal range at all time points; data shown for potassium in Supplement File-Table 1. Electrocardiography recorded at all time points did not show any potassium related abnormality.

Efficacy

Primary Efficacy: Pain (VAS) was reduced at all study time points (Fig 2). The mean change at week 16 from baseline was statistically significantly as per protocol analysis (p=0.039) but not by an intention to treat analysis **(**p=0.17) (Table 5 and Supplement File-Table 2). The mean

change in pain VAS in Arm B (95 % confidence interval -2.99, -1.48) was significantly superior to that in Arm C (adjusted p=0.02) and Arm A (adjusted p=0.04) (Table 4).

Secondary Efficacy: Patients improved in all study groups (Table 4). Numerically superior change was seen in 6 of the 12 efficacy measures (including HAQ function, number of painful joints, general health and Erythrocyte Sedimentation Rate) as compared to Arm B (4 measures) and Arm C (2 measures). The ACR 20 improvement index did not differ by study groups. Interestingly, 7 patients showed ACR 70 index improvement on study completion: 2 in Arm A and 5 in Arm B.

RA Medication

A comprehensive use of medication was described (Table 1, Table 6 and Supplementary File-Table 3). There were no major differences between the study groups although subtle changes were conspicuous. More patients used methotrexate in Arm C on study completion; lesser number in Arm B (Supplement File-Table 3).

Other Results

Clinical: At baseline, the mean systolic/diastolic blood pressure (mm Hg) was 131/79 in Arm A, 129/80 in Arm B and 125/79 in Arm C; correspondingly at week 16 it was 117/80, 116/80 and 126/82. The blood pressure was recorded routinely (sitting position) and not according to a standard protocol.

Serum Cortisol (morning) assay (Supplementary File 1-Table 1): This was an increase in each of the study arms but mostly in Arm B .

Correlation (Supplementary File 1- Table 4): There was a significant but modest inverse correlation between potassium intake and pain VAS (r = -0.19). Urine potassium assay did not correlate with oral potassium intake or serum potassium.

Univariate Analysis (Supplementary File 1- Table 6): Daily potassium intake of 5 gm or more (Odds Ratio 3.14) was significantly associated with low pain VAS (≤ 4 cm).

Logistic (Step forward) Regression (Supplementary File 1, Table 7): A daily potassium intake of 5 gm or more (Likelihood Ratio 2.87) and methotrexate use (Likelihood Ratio 16.1) were significant predictors of low pain VAS when adjusted for several clinical, medication and diet variables.

DISCUSSION

In this randomized controlled study in 172 patients suffering from symptomatic RA despite standard rheumatology care, the joint pain was substantially and significantly reduced by a combination of potassium rich vegetarian diet and a novel potassium enriched food supplement (Arm B) over 16 weeks use as compared to only potassium rich vegetarian diet (Arm A) or routine diet (Arm C, Control). Patients improved for several efficacy measures but this best seen in Arm B followed by Arm B. A daily elemental potassium intake of 5.2 gm (one and half times the preset RDA) was exceeded in 84% participants in Arm B. The safety and tolerability of active potassium intervention was good.

Strengths and Further Implication

To the best of our knowledge, the current study breaks new ground in potassium nutrition and RA. Above all, the study intervention was based on diet and food supplement. There are several

implication of the current study for medical practice and research. Future research should exploit the physiology, and in particular neurological aspects, of potassium for effective and safe management of chronic painful inflammatory disorders such as RA.

An earlier reported potassium deficiency in the diet of RA patients was confirmed by the current study [9]. A suitable vegetarian diet was used to first achieve a RDA for potassium (Arm A) and then a potassium enriched food supplement was added to study the therapeutic effect (Arm B). The oral intake of potassium by several patients in Arm B exceeded 6 gm daily. Assuring, the AE were mild and the tolerance was good. Severe drug toxicity is a main concern with medicinal potassium [8,9]. Though the safe upper limit is not known, healthy subjects are efficient in handling oral potassium intake [8, 26,27]. Diet is the preferred source of potassium [27,28]. Due to regulatory safety concerns, food supplements are restricted in potassium content; in USA it is often less than 100 mg [27, 28, 29]. More scientific research is warranted to revise the recommendations of potassium intake and clinical use.

Several clinical practise issues were addressed as a spin-off. Treat pain or all else will fail is an over-riding clinical dictum and a therapeutic challenge [1,3]. Despite effective treatment, residual joint pain may continue to bother and complicate management [30]. Modern physicians have been skeptical about traditional beliefs (diet and RA) but several studies have unravelled clinical evidence [6,31]. The pain relief and improvement in RA in the current study was remarkable and merits application in clinical practise.

Diet interventional studies are complex and cumbersome [32]. The current study was statistically designed and pragmatic in nature. The participants were well educated (RA) as they had attended the CRD rheumatology clinic (current study site) for several past months and years. The study team had access to their records in the CRD data base (initiated in 1998). Patients were well

matched at randomization baseline. A dietitian (TK) with past experience in food survey, pain and arthritis was engaged from study inception [9,18].

Based on the study methods and the data obtained, we were reasonably confident about the compliance. The diet in Arm C remained unchanged on study completion (Table 2). Several patients, and more so in Arm B, achieved pre-set target for potassium (Table 3 Despite a moderately active symptomatic disease on enrollment , over 90% patients completed the study with nil or subtle changes in the RA medication (Table 6, Supplement File- Table 3). The patients in the active arms were managed with a suitable diet and a food supplement while the control arm used a routine diet; need based analgesics were permitted. The medication decisions were based on the clinical judgement of rheumatologists who were otherwise encouraged to be conservative. In contrast to an obvious increased medication in Arm C, there was a conspicuous reduction in Arm B consistent with a superior improvement.

The inadvertent observation of a lowered mean systolic blood pressure, albeit modest, in the active potassium intervention arms (but not in the control arm) was consistent with the widely reported salubrious effect of potassium on blood pressure [27, 33]. The latter is important because RA is complicated by cardiovascular morbidity and premature mortality [34]. Needless to add, that the blood pressure effect also points towards the study compliance.

Limitations

There were several potentially confounding factors. The compliance to dietary intervention, effect of RA medication, unblinded nature of active intervention and difficulties in recording diet and performing analysis were of special concern right from study inception.

Though the intake of potassium was increased and improvement conspicuous, several patients in Arm A did not achieve the preset RDA (potassium). The spot urinary potassium assay (Supplement File- Table 1) was not consistent and may be due to erratic urine collection. It should be noted that patients in the study remained normokalemic (Supplement File-Table 1). The physiological adjustments to potassium intake are rapid and often not reflected in serum assay [8, 27].

Though there was an overall reduction in analgesic usage in the study, Arm B failed to show a significant change. This might be due to errors in the medication log or difficulties in patient recall. However, according to personal experience (AC), several patients with controlled RA under standard care often surreptitiously resort to unsupervised, preemptive daily use of analgesics out of intense anxiety and fear of impending pain that may interfere with their household chores or livelihood.

Diet is an endearing option to improve RA for the patients and the safety is reassuring. Patients in the current study were aware of their study intervention. Other than a control arm, we could not use a placebo because of restricted funds and local logistic issues. A sixteen-week study period was considered sufficient to meet the study objective. It seems difficult to dismiss a placebo effect in the current study. Placebo effect was reported to be an important limitation in dietary intervention trials and even found in controlled evaluations in RA [32,35]. A retrospective recall of diet and diet analysis using 'Food Composition Tables' as carried out in the current study may introduce some error and nutrients may be underestimated [36].

It was impossible to completely dissect out the clinical benefits of potassium intervention from that of a wholesome vegetarian diet. Vegetarian diet was reported useful in the treatment of RA [37]. We did measure other nutrients but several such as manganese, trace elements and fiber

were left out (Table 2). Potassium intake persisted as a significant predictor for low pain VAS after adjusting several variables including those related to diet (Supplement File- Table 7). Vegetables and fruits are a major source of potassium [27,29].

Other Studies

Several studies reported the benefits of a dominantly vegetarian based Mediterranean diet in RA but did not assess potassium and other potential nutrients [38]. The several clinical benefits of potassium and often in conjunction with a vegetarian diet pertain to osteoporosis, dysbiosis, metabolic abnormalities, catabolic state and debility, cardiovascular dysfunction and blood pressure control [9, 27, 39, 40]. Muscles are a storehouse of potassium and sarcopenia is common in chronic RA [41]. Modulation of potassium ion channels was reported to control pain and immune mediated inflammation [9, 42,43]. However, much more research is warranted.

Mechanism of Action

We do not have a precise explanation to explain the reduction in pain by potassium. We speculate that increased potassium intake (especially therapeutic intervention as in the current study) led to an improved body potassium status, and this caused an increase in endogenous steroids which reduced pain and inflammation. The serum cortisol assay supports the later contention (Supplement File-Table 1). Other mechanisms are also likely and include neurophysiologic effects of potassium and potassium ion channels.

Based on several studies (including animal), the non-chloride forms of potassium which are readily contained in vegetables and fruits have been shown to be more relevant for efficacy and safety; the anion per se mediates some therapeutic benefits such as in bone to reduce resorption [27]. Moderate deficit in body potassium increased blood pressure and other cardiovascular

morbidity which was corrected by potassium chloride supplements [27, 33]. The novel food supplement administered in Arm B in the current study contained both chloride and non-chloride forms of potassium.

Conclusion

A higher oral potassium intake derived from a suitable diet and a novel food supplement improved joint pains considerably in symptomatic patients of chronic RA who were on supervised standard rheumatology care over 16 weeks of use. Several other clinical improvement in RA was also observed. Oral potassium was a useful adjunct and a higher intake (5-7.5 gm daily) was shown to be considerably safe and well tolerated. It would make good clinical sense to advocate a predominantly vegetarian diet with sufficient potassium in the management of RA. Pending further validation, some patients with difficult RA may stand to benefit from a judicious use of a potassium enriched food supplement in addition to standard rheumatology care.

ACKNOWLEDGMENT

Arthritis Research Care Foundation-Centre for Rheumatic Diseases CRD), Pune, India, provided generous material and logistic help for the study. Several colleagues (rheumatologist) assisted in the study and namely Dr Nachiket Kulkarni, Dr Naisar Nahar, and Dr Kiran Adams. Several administrative, nursing and paramedic staff of CRD Pune provided wholehearted assistance and participation. We remain indebted to our patients

who volunteered and consented to participate in the study despite several personal and logistic hurdles.

AUTHORS CONTRIBUTION

All the authors actively participated in drafting and finalizing the version of the current manuscript prior to submission.

Dr Toktam Kianifard and Dr Arvind Chopra shared equally to this manuscript as First Author.

Dr Toktam Kianifard and Dr Arvind Chopra had full access to all of the study data and data analysis and take full responsibility for its integrity and accuracy.

All the authors approved the final version of the manuscript to be published.

Study Conception and design. Kianifard, Chopra

Acquisition of data. Kianifard, Saluja, Venugopalan

Analysis and Interpretation. Kianifard, Sarmukkaddam, Saluja, Venugopalan, Chopra

COMPETING INTERESTS

None of the authors have any competing interest

FUNDING AND SUPPORT

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors and was part of a self-funded PhD program of Dr Toktam Kianifard in University of Pune, Pune, India. None of the authors received any

funding to participate in the research study or for preparing the manuscript for publication. Limited logistic and material support was provided by the Arthritis Research Care Foundation- CRD Pune (India) which is a non-profit making registered charitable research society.

DATA SHARING

The raw data and any other relevant study data duly anonymized for the study participant is available with Dr Arvind Chopra (Senior Author) and access will be provided to an applicant from a non-commercial settings one year after the manuscript is published. The application should be submitted to Dr Arvind Chopra by Email (arvindchopra60@hotmail.com) explaining the reason for access, employability details, protocol and funding of the proposed study, contact details and CV.

REFERENCES

1. O'Dell James R. Treatment of Rheumatoid Arthritis. In: Firestein GS, Budd RC, Gabriel S, McInnes IB, O'Dell JR, eds. Kelley & Firestein's Textbook of Rheumatology. Philadelphia: Elsevier Saunders 2017; 1187-1212.

2. Chopra A. Disease burden of rheumatic diseases in India : COPCORD perspective. *Ind J Rheumatol* 2015; 10: 70-77.

3. Fraenkel L, Bathon JM, England BR, et al..2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research* 2021: 73 (7): 924–939.

4. Chopra A. Ayurvedic medicine and arthritis [Review]. *Rheum Dis Clin North Am* 2000;26:133-144.

5. Vliet Vlieland TP, Pattison D. Non-drug therapies in early rheumatoid arthritis. *Best Practice Res Clin Rheumatol* 2009;23(1):103-16

6. Nelson J, Sjöblom H, Gjertsson I, et al. Do Interventions with Diet or Dietary Supplements Reduce the Disease Activity Score in Rheumatoid Arthritis? A Systematic Review of Randomized Controlled Trials. *Nutrients*. 2020;12(10):2991.

7. Kianifard T, Chopra A. In the absence of specific advice, what do patients eat and avoid? Results from a community based diet study in patients suffering from rheumatoid arthritis with a focus on potassium. *Clinical Nutrition ESPEN* 2018; 28:214-221.

8. Gumz ML, Rabinowitz L, Wingo CS. An Integrated View of Potassium Homeostasis. *N Engl J Med* 2015;373:60-72.

9. Kianifard T, Chopra A. A therapeutic role for potassium (K) to reduce pain and complications related to the cardiovascular system and bone in rheumatoid arthritis (RA): A clinical research perspective. *Rheumatology Research Journal* 2018: 3 (1); 1-12

10. Weber CE . Potassium in the aetiology of rheumatoid arthritis and heart infarction. *Journal of Applied Nutrition* 1974; 26:41-67

11. Kant AK, Graubard BI, Kumanyika SK. Trends in black-white differentials in dietary intakes of U.S. adults, 1971-2002. *American Journal of Preventive Medicine* 2007;32(4):264-272

12. Nuki G, Boddy K, Kennedy AC, et al. Potassium metabolism in patients with rheumatoid arthritis. Effects of treatment with depot tetracosactrin, spironolactone, and oral supplements of potassium chloride. *Ann Rheum Dis* 1975; 34(6): 506-14.

13. Rastmanesh R, Abargouei AS, Shadman Z, et al. A Pilot Study of Potassium Supplementation in the Treatment of Hypokalaemia Patients With Rheumatoid Arthritis: A Randomized, Double-Blinded, Placebo-Controlled Trial. *The Journal of Pain* 2008;9 (8): 722-731

14. National Ethical Guidelines For Biomedical And Health Research Involving Human Participants.2017. Available at URL:https://main.icmr.nic.in/sites/default/files /guidelines/ICMR _Ethical_Guidelines_2017.pdf) (Accessed 10 June 2017)

15. CTRI/2022/03/040726. URL:http://www.ctri.nic.in/Clinicaltrials/showallp.php?mid1=9077&EncHid=&userName=toktam%20kianifard.

16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31:315-324

17. Felson DT, Anderson JJ, Boers M, Bombardier C, Chemoff M, Fried B, et al. American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. *Arthritis Rheum* 1993; 36:729-40

18. Kainifard T, Kianyfard T, Chopra A. Validation and Relevance of Rheumatoid Arthritis Pain Scale (RAPS) in Indian (Asian) patients suffering from rheumatoid arthritis. *Clin Rheumatol* 2015; 34 (9):63-71. DOI 10.1007/s10067-015-3071-2

19. Chopra A, Saluja M., Validation and usefulness of Indian version (CRD Pune) health assessment questionnaire: Drug trials, community practice and COPCORD Bhigwan population study. *Ind J Rheumatol* 2012; 7 (2):74-82

20. Short Form 36. Available at URL:https://www.rand.org/health/surveys_tools/mos/36-item-short-form/ scoring.html. (Accessed 05 Jan 2017)

21. Van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. *J Rheumatol* 1999 ;26(3):705-11

22. Dietary Guidelines for Indians. A Manual. Hyderabad, National Institute of Nutrition- Indian Council of Medical Research publication 2011. Available at URL:http://ninindia.org/DietaryGuidelinesforNINwebsite.pdf (Accessed 12 Jan 2014)

23. Nutritional requirement for Indians. A report of the expert group 2020. Indian Council of Medical Research/ National Institute of Nutrition Hyderabad. Available at URL:http://www.nin.res.in/nutrition2020/RDA-short_report.pdf (Accessed 13 Jan 2014)

24. Kianifard, Toktam. "Composition for Relieving Symptoms of Rheumatoid Arthritis."Government of India Patent 316682. 24 July 2019. Available at URL: https://ipindiaservices.gov.in/publicsearch/ (Accessed 31 Jan 2022)

25. Cohen J. Quantitative methods in Psychology. A Power Primer. *Psychological Bulletin* 1992; 112 (1):155-159

26. EFSA, European Food Safety Authority (2005). Opinion of the NDA Panel related to the Tolerable Upper Intake Level of Potassium. Available at http://www.efsa.europa.eu/en/science/nda/nda_opinions/852.html (Accessed 28 July 2022)

27. Institute of Medicine 2005. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington, DC: The National Academies Press. https://doi.org/10.17226/10925

28. Assessment of dietary intake of potassium in relation to upper guidance level. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safety. VKM Report 2017: 17, ISBN: 978-82-8259-274-1, Oslo, Norway. URL:http://www.vkm.no

29. Potassium Fact Sheet. Available at URL:https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/ (Accessed 13 April 2019)

30. Ishida M, Kuroiwa Y, Yoshida E, et al.. Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. *Modern Rheumatol* 2018; 28 (5): 789-799. DOI:10.1080/14397595.2017.1416940.

31. Philippou E, Nikiphorou E. Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis. *Autoimmun Rev*. 2018 Nov;17(11):1074-1077. doi: 10.1016/j.autrev.2018.05.009. Epub 2018 Sep 10. PMID: 30213695.

32. Staudacher H, Irving P, Lomer M, et al. The challenges of control groups, placebos and blinding in clinical trials of dietary interventions. *Proceedings of the Nutrition Society* 2017;76(3), 203-212. doi:10.1017/S0029665117000350

33. Adrogué HJ, Madias NE. Sodium and Potassium in the Pathogenesis of Hypertension. *N Engl J Med 2007*;356:1966-78

34. Charles-Schoeman C. Cardiovascular disease and rheumatoid arthritis: an update. *Curr Rheumatol Rep* 2012;14(5):455-62. Doi: 10.1007/s11926-012-0271-5.

35. Bechman K, Yates M, Norton S, et al. Placebo Response in Rheumatoid Arthritis Clinical Trials. *J Rheumatol* 2020;47(1):28-34. doi: 10.3899/jrheum.

36. Park Y, Dodd KW, Kipnis V, et al. Comparison of self-automated dietary intakes from the Automated self-administered 24 hours recall, 4-day food records and food frequency questionnaires against recovery biomarkers. *Am J Clin Nutr* 2018; 107 (1):80=93. Doi:10.1093/ajcn/nqx002

37. Alwarith J, Kahleova H, Rembert E, et al. Nutrition Interventions in Rheumatoid Arthritis: The Potential Use of Plant-Based Diets [review] Front. Nutr 2019; 6:141 doi: 10.3389/fnut.2019.00141

38. Senftleber NK , Nielsen SM, Andersen JR, Bliddal H, Tarp S, Lauritzen L et al. Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials. *Nutrients* 2017; 9: 42; doi:10.3390/nu9010042

39. Macdonald HM, Black AJ, Aucott L, et al. Effect of potassium citrate supplementation or increased fruit and vegetable intake on bone metabolism in healthy postmenopausal women: a randomized controlled trial. *Am J Clin Nutr* 2008;88:465–74

40. Horta-Baas G, Romero-Figueroa MDS, Montiel-Jarquín AJ, et al. Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis. *J Immunology Res* 2017 :4835189. doi: 10.1155/2017/4835189.

41. Ngeuleu A, Allali F, Medrare L, et al. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. *Rheumatol Int*. 2017; 37(6):1015-1020

42. Bittner S, Bobak N, Feuchtenberger M, et al. Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients. *Arthritis Research & Therapy* 2011 ;13(1):R21. DOI: 10.1186/ar3245

43. Tsantoulas C, McMahon SB. Opening paths to novel analgesics: the role of potassium channels in chronic pain. *Trends Neurosci*. 2014; 37(3): 146–158.

Table 1: Baseline demographic and other variables: a randomized controlled potassium diet intervention study in patients suffering from rheumatoid arthritis (RA) and on standard care [A: potassium rich diet; B; potassium rich diet plus potassium food supplement; C; routine diet)

Variables	A (n=57)	B (n=57)	C (n=58)	P
Age, mean (years)	50.5 (11.2)	47.3 (12.1)	46.9 (10.5)	0.40*
Women (percent)	85	91	92	0.70**
Duration(years)RA, mean, median	10.6 (8.1), 8	8.5 (7.4),6	7.4 (5.9), 5	0.08*
Body Mass Index, mean (Kg/m^2)	24.4 (3.8)	24.3 (4.3)	24.2(2.9)	0.90*
Erosion hand/joint deformity (percent)	75.4	50.8	62.1	0.15**
Prior continuous DMARD use duration (month), median (range)	26 (6-240)	18 (6-360)	21(6-216)	0.47*
ESR mm fall 1st hour, mean	70.6 (2.2)	68.8 (3.7)	67.4 (3.9)	0.84*
C-reactive protein mg/dl, mean	33.3 (39.4)	26.2 (31.1)	25.5 (37.8)	0.45*
RF seropositive (percent)	76	83	68	0.07**
Serum potassium mEq/l, mean	3.9(0.5)	3.8 (0.6)	3.9 (0.5)	0.59*
Urine potassium mEq/l, mean	44.4 (25.6)	46.7 (25.8)	42.9 (29.1)	0.88*
DMARD single or combination plus Pred use (percent)	70.2	61.4	65.5	0.49**
DMARD single agent only (percent)	19.3	22.8	19	0.89**
Methotrexate use (percent)	82	89	69	0.03**
Sulfasalazine use (percent)	33	19	33	0.19**
Hydroxychloroquine use (percent)	40	40	43	0.80**
Analgesic Use^ (percent)	81	95	90	0.07**

Daily Pred dose mg, mean	5.4 (2.8)	5.3 (2.5)	5.5 (2.3)	0.94*
Weekly Methotrexate dose mg, mean	14.8 (4.4)	14.9 (4.4)	13.9 (4.3)	0.56*
Blood Hemoglobin gm/dl, mean	11.6 (1.3)	11.6 (1.3)	12.1 (1.3)	0.07*

Note: n: number of patients; Percent pertains to proportion of subjects positive; DMARD: disease modifying antirheumatic drug (methotrexate, sulfasalazine, hydroxychloroquine); Pred: prednisolone; Analgesic ^: includes paracetamol and other analgesic use of non-steroidal anti-inflammatory drug/NSAID (diclofenac, naprosyn, etorocoxib, etodolac, nimesulide) more than 4 times a week :*Analysis of variance; **Chi-square statistic using count; */**; significance: $p<0.05$, two tailed; mono: single drug; standard deviation shown in parenthesis after mean; see text for details

Table 2: Median (standard deviation) energy and nutrient consumption daily at baseline (week 0) and study completion (week 16) as per protocol analysis: a randomized controlled potassium diet intervention study in patients suffering from rheumatoid arthritis (RA) and on standard care [A: potassium rich diet; B; potassium rich diet plus potassium food supplement; C; routine diet)

Arm/ Nutrient	A		B		C		p1	p2
	(n=56)		(n=53)		(n=56)			
Time points/week	0	16	0	16	0	16		
Energy (Kcal)	2975 (552.8)	3007 (575.9)	2875 (571.8)	3476 (387.5)	2772 (463.6)	2730 (523.1)	0.14	0.00
Protein (gm)	101 (30.7)	101 (30.8)	96 (28.5)	126 (25.1)	89 (23.9)	89 (20.3)	0.04	0.00
Fat (gm)	72 (6.4)	76 (8.1)	74 (14.6)	91 (32.8)	76 (5.1)	77 (14.8)	0.35	0.09
Zinc (mg)	13 (3.6)	14 (3.5)	13 (3.7)	18 (3.2)	13 (3.2)	11 (8.7)	0.46	0.11
Calcium (mg)	800 (266.4)	693 (285.3)	696 (210.6)	1196 (66.8)	683 (210.1)	607 (155.6)	0.01	0.00
Phosphate(mg)	2198 (527)	2173 (600.5)	2126 (494.3)	2515 (1801.5)	1997 (469.2)	1969 (420.6)	0.08	0.00
Vitamin A (µg)	1181 (598.6)	830 (541.5)	985 (514.1)	1032 (699.4)	1040 (761.1)	869 (646.5)	0.34	0.17
Thiamin (mg)	3 (0.8)	3 (0.1)	3 (0.8)	4 (0.8)	3 (0.7)	3 (0.1)	0.57	0.05
Riboflavin(mg)	2 (0.4)	1 (0.3)	1 (0.4)	2 (0.6)	1 (0.4)	2 (1.3)	0.05	0.27

Niacin (mg)	25 (6.4)	26 (5.2)	25 (6.5)	35 (5.9)	24 (5)	25 (3.9)	0.65	0.07
Vitamin C(mg)	162 (56.1)	163 (47.9)	152 (47.8)	160 (41.8)	172 (73.5)	169 (49.6)	0.15	0.62
Iron (mg)	34 (8.8)	33 (8.9)	31 (8.1)	41 (28.6)	23.3 (15)	30 (13.9)	0.66	0.00
Folic Acid (µg)	421 (161.4)	424.5 (142.8)	393 (139.8)	480 (229.3)	373 (146.1)	308 (109.2)	0.21	0.00
Sodium (mg)	2242 (25.6)	2303 (19.9)	2325 (19.9)	4125 (161.7)	2333 (30.3)	2363 (44)	0.17	0.00
Potassium(mg)	2639 (756.8)	3029 (795.8)	2535 (779.1)	5648 (1281.4)	2531 (985.2)	2651 (873.7)	0.65	0.00

Note: Measure Value rounded to nearest integer and Standard deviation to 1 decimal place; n: number of study participants; p1: p value, ANOVA, comparing baseline (0 weeks); p2: p value, ANOVA, comparing study completion (16 weeks); Food Composition Tables as recommended by National Institution of Nutrition, Hyderabad (See reference serial 23 in text); significant $p<0.05$, two tailed (ANOVA)

Table 3: Number (percent) of patients achieving recommended daily allowance (India) of potassium and further increase compared to randomization baseline: A controlled dietary potassium intervention study (n=172) in chronic Rheumatoid Arthritis [A= potassium rich diet; B=potassium rich diet plus potassium food supplement; C= control routine diet]- per protocol analysis

Arm/Time point week/ Daily Potassium Intake (Target)	A		B		C		P1	P2
	0 (n=57)	16 (n=52)	0 (n=57)	16 (n=50)	0 (n=58)	16 (n=53)		
Daily potassium intake- median (range),90th percentile , mg	2902 (937-4697), 3750	2984 (713-4619), 4150	1863.7 (939-4162), 3400	5708.5 (4365-7545), 6560	2697.5 (680-4645), 3900	1749.8 (1039-4579), 3820	0.68	0.00 (0.02)
Minimal RDA (3500 mg) consumption	14 (25%)	24 (46)	12 (21%)	50(100)	19 (33%)	16 (30)	0.31	0.00 (0.23)
Consumption more than baseline	-	38 (73)	-	50 (100)	-	29 (55)	-	0.00 (0.04)
Consumption more than baseline by 20%	-	23 (44)	-	48 (96)	-	15 (28)	-	0.00 (0.10)
Consumption more than baseline by 50%	-	7 (13)	-	47 (94)	-	10 (19)	-	0.00 (0.29)
Consumption more than 1.5 times RDA (5250 mg)	-	0	-	42 (84)	-	0	-	0.00

Note: Note: n: number of study participants; Target for Arm A: 3200 mg daily (modified RDA for men and women); Target for Arm B: 4800 mg (1.5 times the RDA for women at 3200 mg); 90th percentile is rounded to multiple of 50; ,significant $p < 0.05$, two tailed; P1: comparing baseline-ANOVA (median)/Chi-square (categorical data); P2: comparing study completion week 16 -ANOVA (median)/Chi-square (categorical data); parenthesis in P2 shows comparison of Arm A and Arm C (not adjusted for repeated measure); See Text for details

Table 4: Adverse events (number): a randomized controlled potassium diet intervention study in patients suffering from rheumatoid arthritis (RA) and on standard conventional DMARD with/without steroid treatment [A: potassium rich diet; B; potassium rich diet plus potassium food supplement; C; routine diet)

Adverse Event	A (N = 57)		B (N = 57)		C (N = 58)	
	Total episode	Number of patients	Total episode	Number of patients	Total episode	Number of patients
Nausea	5	4	3	3	4	3
Vomiting	3	3	1	1	1	1
Acid-peptic symptoms	3	3	4	4	4	4
Diarrhea	1	1	2	2	1	1
Constipation	1	1	3	2	2	2
Anorexia	2	2	2	1	2	2
Skin rash	4	4	5	4	2	1
Infections	1	1	3	3	1	1
Vertigo	2	1	0	0	0	0
Oral ulcer	1	1	1	1	0	1
Hair fall	1	1	0	0	2	1
Leucopenia	1	1	0	0	0	0

Note : n: number of patients; Infections include upper/lower respiratory tract infections and urinary infections

Table 5: Efficacy Analysis (per protocol)- showing mean(standard deviation) at randomization baseline and mean change at week 16 (95% confidence interval): a randomized controlled potassium diet intervention study in patients (n=172) suffering from rheumatoid arthritis (RA) and on standard care [A: potassium rich diet; B; potassium rich diet plus potassium food supplement; C; routine diet)

Variable (normal range)	A (n=52)		B(n=50)		C(n-53)		P*
	Base line	Mean change	Base line	Mean change	Base line	Mean change	
Pain visual analogue score (0-10mm)	5.45 (0.88)	-1.31 (-2.19, -0.43)	5.42 (0.84)	-2.23 (-2.99, -1.48)	5.26 (0.95)	-1.25 (-2.03, -0.46)	0.03
Swollen joint count (0-66)	2.36 (2.31)	-1.76 (-2.49, -1.03)	2.46 (2.37)	-0.74 (-2.4, 0.92)	2.5 (3.48)	-1.66 (-3.06, -0.25)	0.27
Painful tender joint count (0-68)	11.19 (9.51)	-8.63 (-12.17,-5.1)	13.11 (10.53)	-8.88 (-12.98, 4.77)	11.96 (10.52)	-6.09 (-11.11, -1.07)	0.42
Patient Global Assess (Grade 1-5)	2.09 (0.56)	-0.55 (-0.91, 0.2)	2.12 (0.82)	-0.6 (-0.98, -0.21)	1.96 (0.63)	-0.26 (-0.6, 0.07)	0.15
Physician Global Assess (Grade 1-5)	1.36 (0.52)	-0.42 (-0.58,-0.27)	1.36 (0.62)	-0.43 (-0.63,-0.19)	1.41 (0.53)	-0.50 (-0.69,-0.30)	0.84
Health assess Questionnaire (0-24)	5.32 (3.43)	-1.94 (-3.22,0.66)	5.11 (3.37)	-2.62 (-4.04, -1.2)	4.60 (3.76)	-0.86 (-2.21, 0.48)	0.05
General Health VAS (0-100)	51.03 (12.66)	13.61 (5.91,21.31)	51.78 (15.12)	14.82 (5.90, 23.73)	50.39 (9.96)	10.92 (3.19, 18.65)	0.61
RA pain Scale (0-144)	61.96 (32.98)	-16.80 (-29.17,4.44)	56 (30.69)	-12.5 (-27.82, 2.82)	63.37 (28.76)	-24.09 (-36.83, -11.35)	0.26
Short Form 36-Physical score	42.24 (6.93)	1.75 (-1.17, 4.69)	41.75 (6.63)	3.03 (0.39, 6.45)	43.39 (5.33)	0.07 (-2.17,	0.15

						2.31)	
Short Form 36-Mental score	40.57 (8.16)	2.34 (-1.05, 5.74)	41.57 (7.23)	1.44 (-1.71, 4.61)	40.49 (7.23)	2.81 (-0.55, 6.18)	0.73
ESR (mm fall end1st hour)	70.48 (29.20)	-8.05 (-17.85, 1.7)	68.76 (28.31)	-11.66 (-22.30, -1.01)	64.05 (28.91)	-8.66 (-17.77, 0.4)	0.76
C-reactive protein (mg/dl)	31.66 (39.40_	-18.31 (-33.10,3.5)	26.89 (31.12)	-8.33 (-18.45,-1.8)	23.23 (37.81)	-8.57 (-23.77, 6.6)	0.33
Disease Activity Score 28 (ESR)	4.85 (0.91)	-1.38 (-1.81, -0.9)	4.97 (1.04)	-1.22 (-1.76, -0.68)	4.84 (0.87)	-1.05 (-1.62, -0.47)	0.46

Note: n: number of patients; ESR: erythrocyte sedimentation rate *: Analysis of Variance ; significant $p<0.05$, two sided; See text for details

Table 6: Mean dose (standard deviation) of weekly methotrexate (mg) and oral daily prednisolone (mg) at randomization baseline (week 0) and study completion (week 16) and difference in mean: A randomized controlled three arm dietary potassium intervention study (n=172) in chronic Rheumatoid Arthritis [A= potassium rich diet; B=potassium rich diet plus potassium food supplement; C= control routine diet]

Drug	Baseline	Completion	Difference	P* (matched sign rank)	p1 (Chi-square)	p2 (Chi-square)
Methotrexate (A)	14.8 (4.4)	15.9 (4.5)	-1.1	0.46	0.56	0.64
Methotrexate (B)	14.9(4.4)	15.2(4.4)	-0.3	0.74		
Methotrexate (C)	13.9(4.3)	15.2 (4.3)	-1.3	0.11		
Prednisolone (A)	5.4 (2.8)	5.7 (2.3)	-0.31	0.43	0.94	0.58
Prednisolone (B)	5.3(2.5)	5.2 (2.3)	0.1	0.16		
Prednisolone (C)	5.5 (2.3)	5.2 (2.1)	0.3	0.91		

Note: Note: n: number of study participants; significant $p < 0.05$; comparison of baseline and completion; p*: p1= baseline comparison of groups, p2= comparison of groups at study completion week 16: See text for details

FIGURE LEGENDS

Fig 1: Patient disposition and number withdrawals- A randomized controlled three arm study of Potassium intervention in rheumatoid arthritis (Arm A: potassium rich diet; Arm B: potassium rich diet plus potassium food supplement; Arm C: routine diet; ITT: intention to treat analysis; PP: per protocol analysis; LFU: lost to follow up; WC: withdrew consent; NC: not protocol compliant ; IR: inadequate treatment response ; see text for details)

Fig 2: Mean pain visual analogue scale at pre-determine study time points- A randomized controlled three arm study of Potassium intervention in rheumatoid arthritis over 16 weeks duration (Arm A: potassium rich diet; Arm B: potassium rich diet plus potassium food supplement; Arm C: routine diet; see text for details)



Fig 1: Patient disposition and number withdrawals- A randomized controlled three arm study of Potassium intervention in rheumatoid arthritis (Arm A: potassium rich diet; Arm B: potassium rich diet plus potassium food supplement; Arm C: routine diet; ITT: intention to treat analysis; PP: per protocol analysis; LFU: lost to follow up; WC: withdrew consent; NC: not protocol compliant ; IR: inadequate treatment response ; see text for details)



Fig 2: Mean pain visual analogue scale at pre-determine study time points- A randomized controlled three arm study of Potassium intervention in rheumatoid arthritis over 16 weeks duration (Arm A: potassium rich diet; Arm B: potassium rich diet plus potassium food supplement; Arm C: routine diet; see text for details)